Status:
COMPLETED
Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye
Lead Sponsor:
Johns Hopkins University
Conditions:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Eligibility:
All Genders
18+ years
Brief Summary
To investigate and compare the burden of dry eye in Sjögren's syndrome dry eye vs non-Sjögren's syndrome dry eye, as well as investigate the diagnostic potential of tear film mucins and various inflam...
Detailed Description
Dry eye is a prevalent ocular disorder worldwide and recognized as one of the most frequent reasons for seeking eye care. Whether locally or systemically initiated, inflammation plays a key role in th...
Eligibility Criteria
Inclusion
- Capacity to give informed consent
- Self-reported literacy
- Best corrected visual acuity at distance 20/40 in each eye
- Signed Institutional Review Board (IRB) approved consent agreeing to terms of the study
- Additional inclusion criteria for the dry eye group (both SS- and non-SS) will include a previous diagnosis of dry eye made by an eye care specialist.
- Differentiation of SS-related versus non-SS dry eye will be made according to the 2016 revised SS classification criteria.
- The classification criteria are based on the weighted sum of the below 5 items:
- • SS laboratory findings
- Anti-Sjogren's Antibody A (SSA) antibody positivity
- Focal lymphocytic sialadenitis with a focus score ≥ 1 foci/mm2
- each scoring=3
- • SS clinical findings
- Abnormal ocular staining score ≥ 5 (or van Bijsterveld score ≥ 4) in one eye
- Schirmer test ≤ 5 mm/5 min (without anesthesia) in one eye
- Unstimulated salivary flow rate ≤ 0.1 mL/min
- each scoring=1
- Individuals who have a total score ≥ 4 for the items above, meet the criteria for primary SS. In other words, for final classification, an individual should have at least one laboratory and one clinical finding.
- Additional inclusion criteria for control subjects will include no previous history of dry eye diagnosis, and no known history of autoimmune disease, verified using a review of systems and past medical history form.
Exclusion
- Age less than 18 years
- Known diagnoses of: Hepatitis C infection, HIV infection, Sarcoidosis, Amyloidosis, Graft Versus Host Disease (GVHD), Cicatrizing conjunctivitis (ie. from trachoma, Stevens-Johnsons Syndrome (SJS), pemphigoid, drug induced pseudo-pemphigoid, or chemical burns, other severe ocular surface diseases such as atopic keratoconjunctivitis
- Physical or mental issues, illiteracy, language problems which might possibly interfere with reading ability or other condition that would preclude successful participation in this study
- Contact lens wear within 10 days of enrollment
- Any intraocular surgery (including cataract surgery) within the last 3 months
- Any minor ocular surgery including tear duct cauterization or plugs, within the last 30 days
- Any history of corneal surgery or cosmetic lid surgery in the past 12 months
- Best corrected vision worse than 20/40
- Pregnant or nursing
- Artificial tear use within 24 hours of study visit
- History of taking or current use of topical prescription eye drops (including, cyclosporine and steroids as well as any glaucoma eye drops).
- Patients who are willing to discontinue their treatment for at least a period of 30 days can be placed on a "wash-out period" as per the discretion of the investigator and patient safety, and be eligible at the end of this period, given all other criteria have been met. Otherwise, patients on these medications will be excluded.
- Any person treated with glaucoma drops in the past (more than 30 days ago) or who had glaucoma surgery (more than 12 months ago) can be included.
- Additional exclusion criteria for control subjects will include previous history of dry eye diagnosis, or history of any known autoimmune, inflammatory or rheumatologic disease including but not limited to Sjögren's syndrome, rheumatoid arthritis, Lupus, mixed connective tissue disease, scleroderma. Also the above exclusion criteria apply to control subjects.
Key Trial Info
Start Date :
January 11 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 3 2022
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT04493658
Start Date
January 11 2021
End Date
October 3 2022
Last Update
January 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wilmer Eye Insitute, Johns Hopkins School of Medicine
Baltimore, Maryland, United States, 21287